Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

Rhythm Pharmaceuticals, Inc.’s RYTM share price has dipped by 10.71%, which has investors questioning if this is right time ...

These five US stocks are defying market trends on new deals, technological breakthroughs, improved sectoral outlook, and ...

Rhythm Pharmaceuticals' Imcivree shows promise in treating obesity from brain damage, reducing BMI by 16.5% in Phase 3 trial; ...

Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

Rhythm Pharmaceuticals met phase 3 endpoint for treating hypothalamic obesity, with regulatory submissions planned for 2025.

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

Rhythm Pharma (RYTM) stock rises as lead asset setmelanotide succeeds in a Phase 3 trial for a rare obesity type, causing an ...

A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI reduction than those receiving placebo, according to top-line results released ...